NCBiotech News

The Wake Forest Institute for Regenerative Medicine has won a $24 million federal grant to model the effects of chlorine gas on human lungs and to develop treatments for chemical injury.

Durham-based Dova Pharmaceuticals plans to merge with a Swedish biopharmaceutical company in a deal that could be worth up to $915 million to Dova’s shareholders.

If you think cool medical science has to happen only where there are medical schools, you don't know how North Carolina does the life sciences these days.

Just take a gander at the beach buzz beginning in Wilmington.

Dan Baden leads a team of scientists at the University of North Carolina Wilmington’s Center for Marine Science. And believe it or not, they're moving in on starting clinical trials with a potentially game-changing cystic fibrosis therapy spun out of a nasty ocean-going algae.

Greensboro's Piedmont Animal Health has received a patent for the formulation platform of its long-acting sterile injectable macrolide antibiotics for administration to companion animals and humans.

If you’re a life science professional looking to take the next career step, but can’t afford to quit your day job, you may want to consider UNC's new online program to earn a Master of Professional Science degree in biomedical and health informatics.

Raleigh’s Eva Garland Consulting, LLC has expanded its partnership with the National Institutes of Health, thanks to a newly awarded contract.

Pfizer, the international biopharmaceutical giant, is expanding its gene therapy program with the purchase of a Durham property that will become a clinical manufacturing facility.

NIH has launched a massive effort to develop better flu vaccines, awarding the Duke Human Vaccine Institute three contracts worth up to $400 million over seven years.

RTP's CivaTech Oncology has received marketing approval from the FDA for its new CivaDerm skin cancer treatment "bandage."

Durham's Ribometrix, started with funding help from NCBiotech, will partner with Vertex Pharmaceuticals of Boston to discover and develop drug candidates in a deal that could ultimately be worth more than $700 million to Ribometrix.

Knowledge is power. Work smarter not harder. Both principles drove the third annual Informing Innovation 2019 event hosted recently by the Life Science Intelligence team at the North Carolina Biotechnology Center.

Type 2 diabetes patients may soon have an option to inhale insulin through a device from Durham's Aerami Therapeutics that acts faster and lasts longer than Lilly’s injected insulin.

Morrisville-based Locus Biosciences, a developer of precision antibacterial therapies, joins companies from the U.S., Belgium, the U.K. and Spain named to the prestigious "Fierce 15" listing of the world's hottest biotech companies.

A $1.1 million U.S. Department of Defense grant will support Morrisville-based Novan’s efforts to develop a new defense against cervical cancer.

Hanging on to North Carolina's dominance in agricultural technology requires continued investment and innovation, said panelists at the North Carolina Biotechnology Center’s September AgTech Professional Forum.